Literature DB >> 18071056

Ethnic and genetic determinants of cardiovascular response to the selective alpha 2-adrenoceptor agonist dexmedetomidine.

Daniel Kurnik1, Mordechai Muszkat, Gbenga G Sofowora, Eitan A Friedman, William D Dupont, Mika Scheinin, Alastair J J Wood, C Michael Stein.   

Abstract

The alpha(2)-adrenoceptor agonist clonidine reduces blood pressure more effectively in White than Black Americans despite similar degrees of sympatholysis. Functional genetic variation in receptor signaling mechanisms, for example in the beta 3 G-protein subunit (GNB3 C825T) and in the alpha(2C)-adrenoceptor subtype (ADRA2C del322-325), may affect drug responses. We examined the hypothesis that there are ethnic differences in the responses to the highly selective alpha(2)-agonist, dexmedetomidine, and that these genetic variants contribute to interindividual variability in drug responses. In a placebo-controlled, single-masked study, 73 healthy subjects (37 whites and 36 blacks) received 3 placebo infusions and then 3 incremental doses of dexmedetomidine (cumulative dose, 0.4 microg/kg), each separated by 30 minutes. Blood pressure, heart rate, and plasma catecholamine concentrations were determined after each infusion. We measured dexmedetomidine concentrations after the last infusion and determined ADRA2C del322-325 and GNB3 C825T genotypes. Dexmedetomidine lowered blood pressure and plasma catecholamine concentrations significantly (all P<0.001). There was substantial interindividual variability in the reduction of systolic blood pressure (range, 1 to 34 mm Hg) and plasma norepinephrine concentrations (range, 24 to 424 pg/mL). However, there were no differences between black and white subjects in dexmedetomidine responses (P>0.16 for all outcomes) before or after adjustment for covariates. Neither ADRA2C del322-325 nor GNB3 C825T genotypes affected the responses to dexmedetomidine (all P>0.66). There is large interindividual variability in response to the selective alpha(2)-AR agonist dexmedetomidine, and neither ethnicity nor ADRA2C and GNB3 genotypes contribute to it. Further studies to identify determinants of alpha(2)-AR-mediated responses will be of interest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18071056     DOI: 10.1161/HYPERTENSIONAHA.107.098939

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  16 in total

1.  Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans.

Authors:  Utkarsh Kohli; Maureen K Hahn; Brett A English; Gbenga G Sofowora; Mordechai Muszkat; Chun Li; Randy D Blakely; C Michael Stein; Daniel Kurnik
Journal:  Pharmacogenet Genomics       Date:  2011-04       Impact factor: 2.089

2.  A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study.

Authors:  Leena Choi; Brian S Caffo; Utkarsh Kohli; Pratik Pandharipande; Daniel Kurnik; E Wesley Ely; C Michael Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-08-17       Impact factor: 2.745

3.  The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery.

Authors:  Seyhan Yağar; Soner Yavaş; Bensu Karahalil
Journal:  Mol Biol Rep       Date:  2010-11-23       Impact factor: 2.316

4.  Genetic variations in the α(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine.

Authors:  Daniel Kurnik; Mordechai Muszkat; Chun Li; Gbenga G Sofowora; Eitan A Friedman; Mika Scheinin; Alastair J J Wood; C Michael Stein
Journal:  Circ Cardiovasc Genet       Date:  2011-02-15

5.  Lack of effect of the alpha2C-adrenoceptor Del322-325 polymorphism on inhibition of cyclic AMP production in HEK293 cells.

Authors:  M D Montgomery; D B Bylund
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

6.  Patient predictors of dexmedetomidine effectiveness for sedation in intensive care units.

Authors:  Pamela L Smithburger; Randall B Smith; Sandra L Kane-Gill; Philip E Empey
Journal:  Am J Crit Care       Date:  2014-03       Impact factor: 2.228

7.  Variation in the α(2A) adrenoceptor gene and the effect of dexmedetomidine on plasma insulin and glucose.

Authors:  Laxmi V Ghimire; Mordechai Muszkat; Gbenga G Sofowora; Mika Scheinin; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Pharmacogenet Genomics       Date:  2013-09       Impact factor: 2.089

8.  Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.

Authors:  Utkarsh Kohli; Mordechai Muszkat; Gbenga G Sofowora; Paul A Harris; Eitan A Friedman; William D Dupont; Mika Scheinin; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Eur J Pain       Date:  2009-05-06       Impact factor: 3.931

9.  Blacks have a greater sensitivity to α1-adrenoceptor-mediated venoconstriction compared with whites.

Authors:  Abiodun Adefurin; Laxmi V Ghimire; Utkarsh Kohli; Mordechai Muszkat; Gbenga G Sofowora; Sachin Y Paranjape; C Michael Stein; Daniel Kurnik
Journal:  Hypertension       Date:  2013-02-11       Impact factor: 10.190

10.  Dexmedetomidine-induced cerebral hypoperfusion exacerbates ischemic brain injury in rats.

Authors:  Takaaki Nakano; Hirotsugu Okamoto
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.